Literature DB >> 19869370

STUDIES ON THE OXIDATION AND REDUCTION OF IMMUNOLOGICAL SUBSTANCES : IX. THE ERYTHROCYTE-COMBINING PROPERTY OF PNEUMOCOCCUS HEMOTOXIN.

W L Fleming1, J M Neill.   

Abstract

The investigation dealt particularly with the combination of pneumococcus hemotoxin with red blood cells. The reduced or hemolytically active form of the hemotoxin was known to possess the property of erythrocyte combination. The results obtained in this study indicate that the hemolytically inactive, reversibly oxidized form exists in two different modifications; one retains the property of erythrocyte combination while the other lacks this property. The influence of the combining property of the hemotoxin upon the mechanism of hemolysis and upon the inhibition of the hemolytic reaction was also investigated.

Entities:  

Year:  1927        PMID: 19869370      PMCID: PMC2131314          DOI: 10.1084/jem.46.5.755

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  2 in total

1.  STUDIES ON THE OXIDATION-REDUCTION OF HEMOGLOBIN AND METHEMOGLOBIN : III. THE FORMATION OF METHEMOGLOBIN DURING THE OXIDATION OF AUTOXIDIZABLE SUBSTANCES.

Authors:  J M Neill
Journal:  J Exp Med       Date:  1925-03-31       Impact factor: 14.307

2.  STUDIES ON THE OXIDATION AND REDUCTION OF IMMUNOLOGICAL SUBSTANCES : VI. THE "REACTIVATION" OF THE BACTERIOLYTIC ACTIVITY OF OXIDIZED PNEUMOCOCCUS EXTRACTS.

Authors:  J M Neill; W L Fleming
Journal:  J Exp Med       Date:  1927-07-31       Impact factor: 14.307

  2 in total
  2 in total

1.  The purification and properties of streptolysin S.

Authors:  B CINADER; L PILLEMER
Journal:  J Exp Med       Date:  1950-09       Impact factor: 14.307

2.  STUDIES ON THE OXIDATION AND REDUCTION OF IMMUNOLOGICAL SUBSTANCES : X. IMMUNOLOGICAL DISTINCTIONS BETWEEN THE HEMOTOXIN AND THE "PROTEIN FRACTION" OF THE PNEUMOCOCCUS CELL.

Authors:  J M Neill; W L Fleming; E L Gaspari
Journal:  J Exp Med       Date:  1927-10-31       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.